TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: Daratumumab, which is used for CD30-positive cutaneous T-cell lymphoma, was recommended as a treatment option after the failure of at least one systemic therapy in adults when combined with bortezomib and dexamethasone.